This Personalized Cancer Test Changed The Course Of My Treatment

Reported by Women's Health Magazine.

When Sabrina M. found an unusual indentation in her breast in 2011, she had no reason to expect the worst. The 40-year-old ER nurse and mother of three was healthy, active, and had none of the textbook risk factors. But within weeks, she had a breast cancer diagnosis — and two oncologists pushing two different aggressive chemotherapy regimens. "I didn't know what to do," she says. Faced with conflicting advice and a clock ticking, she sought a third opinion. That decision changed everything.

Her third oncologist pointed her toward the Oncotype DX Breast Recurrence Score® test — a genomic tool that analyzes 21 genes from a patient's tumor to predict the likelihood of distant recurrence and whether chemotherapy will actually help. According to Women's Health Magazine, the test has since informed treatment decisions for more than two million patients globally and is now considered standard of care for early-stage, HR+, HER2-negative breast cancers. It requires no additional procedures — just the tissue already collected during biopsy or surgery — and delivers results in roughly two weeks.

What Your Genes Know That a Scan Doesn't

Before genomic testing existed, oncologists leaned on tumor size, grade, and lymph node involvement to map a treatment plan. That framework, it turns out, was incomplete. Marcela Mazo Canola, MD, an oncologist and assistant professor of medicine in San Antonio who specializes in breast cancer research, puts it plainly: "Genes are actually what matter." A small tumor can carry ferociously aggressive genetics; a larger one might fold under endocrine therapy alone. The test's Recurrence Score® result — a personalized number — tells patients and their doctors which scenario they're actually dealing with, and whether chemotherapy adds any meaningful benefit.

Sabrina had already gone wig shopping by the time her results came back. Her score: 10 — low enough to skip chemo entirely. Instead, she completed a short course of radiation followed by five years of hormone therapy. The side effects weren't nothing — fatigue, nausea, menopausal symptoms — but she finished treatment in 2021 and has spent the years since leaning hard into life. She earned her PhD in nursing and now works as an oncology nurse navigator, guiding other patients through clinical trials. The wig stayed on the shelf.

Dr. Mazo Canola now runs the test on every qualifying patient in her practice, citing over two decades of clinical validation and confirmed performance across diverse racial and ethnic populations — a critical bar that many tools don't clear. The test is used in more than 100 countries and remains the only genomic test proven to predict chemotherapy benefit. Her advice for anyone newly diagnosed: "Don't go on the assumption that you automatically need chemotherapy." Push for the full picture first. Visit breastcancerclarity.com to learn more, and ask your doctor whether the Oncotype DX test is right for you.

The bottom line: when it comes to breast cancer treatment, more information isn't just reassuring — it can be the difference between chemo you need and chemo you don't.

Read the original at Women's Health Magazine.